First Manhattan CO Prothena Corp Public LTD CO Transaction History

First Manhattan CO

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $74 - $121	3 New	3 $0
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $140 - $174	-3 Reduced 0.8%	374 $18,000
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $19,622 - $24,505	377 New	377 $22,000
Q1 2020 May 06, 2020	SELL	$7.54 - $15.77 $746 - $1,561	-99 Closed	0 $0
Q4 2018 Jan 30, 2019	SELL	$8.73 - $13.74 $881 - $1,387	-101 Reduced 50.5%	99 $1,000

Q3 2018 Oct 15, 2018	BUY	$12.7 - $15.79 $2,540 - $3,158	200 New	200 $2,000
Q1 2018 Apr 20, 2018	SELL	$27.95 - $45.04 $3 Million - $4.83 Million	-107,200 Closed	0 $0
Q4 2017 Jan 22, 2018	BUY	$35.44 - $63.76 $2.03 Million - $3.65 Million	57,200 Added 114.4%	107,200 $4.02 Million
Q3 2017 Oct 25, 2017	BUY	$53.83 - $67.75 $2.69 Million - $3.39 Million	50,000	50,000 $3.24 Million

217

34.9M

656K

1.12M

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $481M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

Stay updated on First Manhattan CO with notifications on news.